Entrada Therapeutics (TRDA) Competitors $6.00 +0.08 (+1.35%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$5.99 -0.01 (-0.17%) As of 07:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRDA vs. URGN, TSHA, MNMD, ABUS, RZLT, SANA, KOD, XNCR, SEPN, and PHATShould you be buying Entrada Therapeutics stock or one of its competitors? The main competitors of Entrada Therapeutics include Urogen Pharma (URGN), Taysha Gene Therapies (TSHA), Mind Medicine (MindMed) (MNMD), Arbutus Biopharma (ABUS), Rezolute (RZLT), Sana Biotechnology (SANA), Kodiak Sciences (KOD), Xencor (XNCR), Septerna (SEPN), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical products" industry. Entrada Therapeutics vs. Its Competitors Urogen Pharma Taysha Gene Therapies Mind Medicine (MindMed) Arbutus Biopharma Rezolute Sana Biotechnology Kodiak Sciences Xencor Septerna Phathom Pharmaceuticals Entrada Therapeutics (NASDAQ:TRDA) and Urogen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings. Which has higher valuation and earnings, TRDA or URGN? Entrada Therapeutics has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntrada Therapeutics$79.48M2.87$65.63M-$1.78-3.37Urogen Pharma$90.40M8.90-$126.87M-$3.32-5.24 Does the media prefer TRDA or URGN? In the previous week, Urogen Pharma had 8 more articles in the media than Entrada Therapeutics. MarketBeat recorded 9 mentions for Urogen Pharma and 1 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 1.34 beat Urogen Pharma's score of 0.38 indicating that Entrada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Urogen Pharma 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is TRDA or URGN more profitable? Entrada Therapeutics has a net margin of -92.30% compared to Urogen Pharma's net margin of -164.44%. Entrada Therapeutics' return on equity of -17.81% beat Urogen Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Entrada Therapeutics-92.30% -17.81% -14.55% Urogen Pharma -164.44%-97,487.15%-59.38% Do analysts prefer TRDA or URGN? Entrada Therapeutics presently has a consensus price target of $25.67, indicating a potential upside of 327.78%. Urogen Pharma has a consensus price target of $32.00, indicating a potential upside of 83.91%. Given Entrada Therapeutics' higher possible upside, analysts plainly believe Entrada Therapeutics is more favorable than Urogen Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entrada Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67Urogen Pharma 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.80 Do insiders & institutionals believe in TRDA or URGN? 86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 8.1% of Entrada Therapeutics shares are owned by company insiders. Comparatively, 4.7% of Urogen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility & risk, TRDA or URGN? Entrada Therapeutics has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500. SummaryEntrada Therapeutics beats Urogen Pharma on 9 of the 16 factors compared between the two stocks. Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRDA vs. The Competition Export to ExcelMetricEntrada TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$228.22M$3.35B$6.11B$10.54BDividend YieldN/A2.28%5.66%4.69%P/E Ratio-3.3722.2886.8426.71Price / Sales2.87265.33533.69203.04Price / Cash3.7846.3226.3031.09Price / Book0.529.9012.606.57Net Income$65.63M-$52.45M$3.30B$276.78M7 Day Performance2.74%5.05%3.54%1.96%1 Month Performance13.42%10.61%6.78%9.11%1 Year Performance-64.85%25.03%71.47%31.60% Entrada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRDAEntrada Therapeutics3.1432 of 5 stars$6.00+1.4%$25.67+327.8%-64.9%$228.22M$79.48M-3.37110Positive NewsURGNUrogen Pharma3.951 of 5 stars$19.03-0.6%$32.00+68.2%+37.0%$885.69M$90.40M-5.77200Analyst ForecastTSHATaysha Gene Therapies2.5471 of 5 stars$3.19+0.8%$8.29+160.1%+136.8%$868.87M$8.33M-9.37180Trending NewsGap UpMNMDMind Medicine (MindMed)2.3351 of 5 stars$11.45-4.9%$26.50+131.4%+125.5%$867.05MN/A-7.4540ABUSArbutus Biopharma1.246 of 5 stars$4.46+1.1%$5.00+12.1%+14.1%$848.46M$6.17M-15.2690RZLTRezolute2.8038 of 5 stars$9.21-0.9%$14.50+57.5%+84.6%$835.91MN/A-9.4940SANASana Biotechnology3.0149 of 5 stars$3.49-1.3%$7.50+114.7%-6.4%$828.77MN/A-3.29380KODKodiak Sciences3.0098 of 5 stars$15.53-1.8%$13.00-16.3%+466.2%$822.25MN/A-4.1090XNCRXencor2.6174 of 5 stars$11.61+0.4%$22.25+91.6%-40.7%$821.96M$110.49M-4.80280SEPNSepterna1.4697 of 5 stars$18.28+0.7%$26.75+46.3%N/A$815.01M$1.08M-1.81N/APHATPhathom Pharmaceuticals1.9654 of 5 stars$11.63-1.2%$17.50+50.4%-29.2%$804.18M$55.25M-2.40110 Related Companies and Tools Related Companies Urogen Pharma Alternatives Taysha Gene Therapies Alternatives Mind Medicine (MindMed) Alternatives Arbutus Biopharma Alternatives Rezolute Alternatives Sana Biotechnology Alternatives Kodiak Sciences Alternatives Xencor Alternatives Septerna Alternatives Phathom Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRDA) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
